Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio
Disappointing clinical trial results from Sanofi and Regeneron raise questions about the future role that certain drugs might have in treating asthma and other inflammatory related diseases.
by Adam Feuerstein
Jun 21, 2019
1 minute
Sanofi (SNY) and Regeneron Pharmaceuticals () said Friday that a monoclonal antibody drug targeting a protein called IL-33 provided no additional benefit to asthma patients when added to the already approved drug Dupixent.
You’re reading a preview, subscribe to read more.
Start your free 30 days